Roche buys rights to Sarepta’s DMD gene therapy
Sarepta will receive $1.15 billion upfront and an equity investment
Read More
Tag: Sarepta
Sarepta’s DMD drug hit with FDA Complete Response Letter
The company say they are “surprised” to have received the letter.
Read More
CHMP takes negative view on Sarepta’s DMD therapy
Sarepta has indicated a delay to getting its Duchenne muscular dystrophy therapy Exondys approved in Europe, revealing that the European Medicine Agency’s Committee for Medicinal Products for Human Use’s trend vote was negative.
Read More
FDA OKs first Duchenne muscular dystrophy drug
The US Food and Drug Administration has granted a conditional approval to Sarepta’s Exondys 51, the first drug cleared to treat patients with Duchenne muscular dystrophy (DMD).
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
